Alexanian R, Yap B S, Bodey G P
Blood. 1983 Sep;62(3):572-7.
The utility of vindesine and a frequent prednisone schedule was evaluated in 70 patients with refractory myeloma. No patient responded to vindesine alone, but about one-fourth achieved significant tumor reductions from intermittent high-dose prednisone, either alone or in combination with vindesine. Forty-seven percent responded when prednisone pulses were combined with vincristine and doxorubicin, providing the best results yet achieved in our patients with refractory myeloma. In responding patients, remissions were of excellent quality and survival was prolonged significantly. These results supported the utility of a more frequent corticosteroid schedule with increased doxorubicin dose in patients with advanced and resistant multiple myeloma.
对70例难治性骨髓瘤患者评估了长春地辛及频繁使用泼尼松方案的疗效。单独使用长春地辛时无患者有反应，但约四分之一的患者通过间歇性大剂量泼尼松单独使用或与长春地辛联合使用，实现了肿瘤显著缩小。当泼尼松脉冲疗法与长春新碱和多柔比星联合使用时，47%的患者有反应，这是我们难治性骨髓瘤患者迄今取得的最佳结果。有反应的患者缓解质量良好，生存期显著延长。这些结果支持了在晚期和耐药性多发性骨髓瘤患者中采用更频繁的皮质类固醇方案并增加多柔比星剂量的实用性。
